Skip to content
2019 Cardio-Oncology Survey - FLASCO Membership
1.
How would you rate your knowledge of Cardio Oncology, cancer and heart disease ?
very high
some knowledge
neutral
little knowledge
no knowledge
2.
How comfortable are you treating patients with cancer therapy related cardiac toxicities?
very comfortable
somewhat comfortable
neutral
uncomfortable
3.
What is your most common approach to cardiovascular events, complications, or treatment of cardiovascular risk factors in patients with cancer prior or during their treatment/chemotherapy?
consult to internist
general cardiologist
cardio-oncologist
refer them out of town due to lack of local resources
4.
What are the 3 most common cardiovascular toxic effects you have seen in your service? Please name the relevant cancer therapy medication for each. (i.e. decline in LVEF/heart failure, myocardial ischemia, pericarditis, myocarditis, valvular heart disease, arrhythmia, venous or arterial thromboembolic events, pulmonary hypertension, QT prolongation)
5.
How often/commonly do your patients face potential cardiotoxicity caused by cancer therapies in your service?
Very often-every day
Common-more than once per week
Not often - less than once per week
More than once per month
Rarely-less than once per month
6.
Are there dedicated cardio oncology services in your hospital/community?
yes
no
I don’t know
If yes, have you referred any patients to those services?
7.
What level of cooperation do you have with your local cardiologists for co-management of cardiovascular complications of cancer treatment?
excellent
some cooperation
neutral
little cooperation
no cooperation
8.
Are there local cardio oncology educational resources in your community? (i.e. conferences or tumor boards with cardiology input case presentation meetings)
yes
no
9.
Would you find these resources of value?
yes
no
10.
What are the main barriers in establishing a cardio oncology program/practice in your community: (check all that apply)
lack of awareness
lack of mentoring
lack of interest
lack of financial resources
inadequate reimbursement
not considered important
political/employer referral bias
11.
How many educational programs or sessions in Cardio Oncology or Cardiovascular complications of cancer treatment have you attended in the last 3-5 years?
none
1
2-3
>3
12.
Are there any important issues concerning Cancer and Cardio-vascular diseases in your community that need be addressed?
13.
Please provide the following demographics: age, gender, type of practice (private/academic/hospital employed/single vs specialty group)
14.
Are you familiar with the cardiotoxicity of the following cancer therapies?
Yes
NO
Anthracyclines: doxorubicine, daunorubicine, idarubicin, epirubicin, mitoxantrone
Yes
NO
Platinum : cisplatin, carboplantin, oxaliplatin
Yes
NO
Antimetabolites: Fluorouracil, Capecitabine
Yes
NO
Alkylating agents : Cyclophosphamide
Yes
NO
Antimicrotubule agent : Paclitaxel
Yes
NO
HER2 inhibitors: Trastuzumab, Pertuzumab, trastuzumab emtansine, lapatinib
Yes
NO
VEGF signaling pathway inhibitors: Bevacizumab, Aflibercept, Ramucirumab, Sunitinib, sorafenib, pazopanib, axitinib, vandetanib, regorafenib, cabozantinib, lenvatinib
Yes
NO
Multitargeted tyrosine kinase inhibitors: dasatinib, nilotinib, Ponatinib
Yes
NO
Other multitargeted tyrosine kinase inhibitors: crizotinib, ceritinib, everolimus, temsirolimus, ibrutinib, trametinib
Yes
NO
Immunomodulatory drug: thalidomide, lenalidomide, pomalidomide
Yes
NO
Proteasome inhibitors: bortezomib, carfilzomib
Yes
NO
Immune checkpoint inhibitors: Pembrolizumab, nivolumab, Ipilimumab
Yes
NO
15.
Which of the following medications will motivate you to perform a formal cardiac evaluation?
Yes
NO
Anthracyclines: doxorubicine, daunorubicine, idarubicin, epirubicin, mitoxantrone
Yes
NO
Platinum : cisplatin, carboplantin, oxaliplatin
Yes
NO
Antimetabolites: Fluorouracil, Capecitabine
Yes
NO
Alkylating agents : Cyclophosphamide
Yes
NO
Antimicrotubule agent : Paclitaxel
Yes
NO
HER2 inhibitors: Trastuzumab, Pertuzumab, trastuzumab emtansine, lapatinib
Yes
NO
VEGF signaling pathway inhibitors: Bevacizumab, Aflibercept, Ramucirumab, Sunitinib, sorafenib, pazopanib, axitinib, vandetanib, regorafenib, cabozantinib, lenvatinib
Yes
NO
Multitargeted tyrosine kinase inhibitors: dasatinib, nilotinib, Ponatinib
Yes
NO
Other multitargeted tyrosine kinase inhibitors: crizotinib, ceritinib, everolimus, temsirolimus, ibrutinib, trametinib
Yes
NO
Immunomodulatory drug: thalidomide, lenalidomide, pomalidomide
Yes
NO
Proteasome inhibitors: bortezomib, carfilzomib
Yes
NO
Immune checkpoint inhibitors: Pembrolizumab, nivolumab, Ipilimumab
Yes
NO
16.
Which of the following cancer therapies have you seen, in your practice, cause cardio toxicity?
Yes
NO
Anthracyclines: doxorubicine, daunorubicine, idarubicin, epirubicin, mitoxantrone
Yes
NO
Platinum : cisplatin, carboplantin, oxaliplatin
Yes
NO
Antimetabolites: Fluorouracil, Capecitabine
Yes
NO
Alkylating agents : Cyclophosphamide
Yes
NO
Antimicrotubule agent : Paclitaxel
Yes
NO
HER2 inhibitors: Trastuzumab, Pertuzumab, trastuzumab emtansine, lapatinib
Yes
NO
VEGF signaling pathway inhibitors: Bevacizumab, Aflibercept, Ramucirumab, Sunitinib, sorafenib, pazopanib, axitinib, vandetanib, regorafenib, cabozantinib, lenvatinib
Yes
NO
Multitargeted tyrosine kinase inhibitors: dasatinib, nilotinib, Ponatinib
Yes
NO
Other multitargeted tyrosine kinase inhibitors: crizotinib, ceritinib, everolimus, temsirolimus, ibrutinib, trametinib
Yes
NO
Immunomodulatory drug: thalidomide, lenalidomide, pomalidomide
Yes
NO
Proteasome inhibitors: bortezomib, carfilzomib
Yes
NO
Immune checkpoint inhibitors: Pembrolizumab, nivolumab, Ipilimumab
Yes
NO
Current Progress,
0 of 16 answered